{
    "clinical_study": {
        "@rank": "102544", 
        "acronym": "INPRES", 
        "arm_group": [
            {
                "arm_group_label": "standard care", 
                "arm_group_type": "No Intervention", 
                "description": "everolimus dose is continued independently of everolimus AUC"
            }, 
            {
                "arm_group_label": "everolimus dose escalation", 
                "arm_group_type": "Active Comparator", 
                "description": "patients with an AUC below mean will have dose escalation of everolimus based on their AUC"
            }
        ], 
        "brief_summary": {
            "textblock": "A study to determine whether everolimus pharmacokinetics in elderly and obese patients is\n      different compared to control patients.\n\n      Furthermore the investigators will investigate the relation between metabolic response\n      assessed with [18F] Fluorodeoxyglucose-Positron Emission Tomography (FDG-PET) and everolimus\n      exposure and clinical benefit.\n\n      The investigators will explore whether dose escalation in patients who are hypothetically\n      underexposed will result in an increase in metabolic response."
        }, 
        "brief_title": "Influence of Exceptional Patient Characteristics on Everolimus Exposure", 
        "condition": "Breast Neoplasms", 
        "condition_browse": {
            "mesh_term": [
                "Breast Neoplasms", 
                "Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult women (\u2265 18 years of age) with metastatic or locally advanced breast cancer not\n             amenable to curative treatment by surgery or radiotherapy.\n\n          -  Histological or cytological confirmation of estrogen-receptor positive (ER+) breast\n             cancer\n\n          -  Postmenopausal women\n\n          -  Radiological or clinical evidence of recurrence or progression on last systemic\n             therapy prior to enrollment.\n\n          -  Progression following a non-steroidal aromatase inhibitor\n\n          -  Falling into one of the following categories\n\n               -  elderly patients (age \u2265 70 years and BMI < 30 kg/m2); or\n\n               -  obese patients (BMI \u2265 30 kg/m2 and age < 70 years); or\n\n               -  control patients (BMI < 30 kg/m2 and age < 70 years);\n\n          -  Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \u2264 5 x ULN\n\n          -  Adequate renal function: calculated creatinine clearance, as estimated by GFR using\n             the MDRD formula, is \u2265 30ml/min/1.73m2\n\n          -  Performance status ECOG 0 - 2 (Karnofsky index: 60 - 100)\n\n          -  Patient is willing and able to sign the Informed Consent Form prior to screening\n             evaluations\n\n        Exclusion Criteria:\n\n          -  Patients aged \u2265 70 years AND BMI \u2265 30 kg/m2\n\n          -  HER2-overexpressing patients by local laboratory testing (IHC 3+ staining or in situ\n             hybridization positive).\n\n          -  Previous treatment with exemestane or mTOR inhibitors. Except for the treatment with\n             exemestane in the adjuvant setting.\n\n          -  Known hypersensitivity to mTOR inhibitors, e.g. sirolimus (rapamycin).\n\n          -  Patients with a known history of HIV seropositivity.\n\n          -  Any severe and / or uncontrolled medical conditions such as:\n\n               -  Unstable angina pectoris, serious uncontrolled cardiac arrhythmia\n\n               -  Patients with severe hepatic impairment (Child-Pugh A/B/C)\n\n               -  Uncontrolled diabetes mellitus\n\n               -  Impairment of gastrointestinal function or gastrointestinal disease that may\n                  significantly alter the absorption of study drugs (e.g., ulcerative disease,\n                  uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome)\n\n          -  Patients who test positive for hepatitis B or C\n\n          -  Patients being treated with drugs recognized as being strong inhibitors or inducers\n             of the isoenzyme CYP3A within the last 5 days prior to enrollment\n\n          -  History of non-compliance to medical regimens\n\n          -  Patients unwilling to or unable to comply with the protocol"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "75", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 13, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01948960", 
            "org_study_id": "UMCNONCO201301"
        }, 
        "intervention": {
            "arm_group_label": "everolimus dose escalation", 
            "description": "patients with an AUC below mean will have dose escalation of everolimus based on their AUC", 
            "intervention_name": "everolimus dose escalation", 
            "intervention_type": "Drug", 
            "other_name": "Everolimus dose escalation"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Everolimus", 
                "Sirolimus"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Breast Neoplasms", 
            "everolimus", 
            "pharmacokinetics", 
            "elderly patients", 
            "obese patients"
        ], 
        "lastchanged_date": "November 7, 2013", 
        "location": {
            "contact": {
                "email": "annelieke.willemsen@radboudumc.nl", 
                "last_name": "Annelieke Willemsen, MD"
            }, 
            "facility": {
                "address": {
                    "city": "Nijmegen", 
                    "country": "Netherlands"
                }, 
                "name": "Radboud university medical center"
            }, 
            "investigator": {
                "last_name": "Carla van Herpen, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Netherlands"
        }, 
        "number_of_arms": "2", 
        "official_title": "Influence of Exceptional Patient Characteristics on Everolimus Exposure", 
        "overall_contact": {
            "email": "Carla.vanHerpen@radboudumc.nl", 
            "last_name": "Carla van Herpen, MD, PhD"
        }, 
        "overall_contact_backup": {
            "email": "Annelieke.Willemsen@radboudumc.nl", 
            "last_name": "Annelieke Willemsen, MD"
        }, 
        "overall_official": [
            {
                "affiliation": "Radboud university medical center, department of medical oncology", 
                "last_name": "Carla van Herpen, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Radboud university medical center, department of Pharmacy", 
                "last_name": "Nielka van Erp, PharmD, PhD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary aim is to show a difference in everolimus exposure (AUC0-24hr) of at least 25% in elderly patients (\u226570 years) and obese patients (BMI \u2265 30 kg/m2) compared to the control group (\u2264 70 years; BMI \u2264 30 kg/m2), after reaching steady state everolimus pharmacokinetics (day 14, but at least after 7 days of everolimus therapy).", 
            "measure": "everolimus AUC", 
            "safety_issue": "No", 
            "time_frame": "day 14 after start treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01948960"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "To explore and calculate the predictive value of early metabolic response assessment with clinical benefit (PFS defined as disease progression according to RECIST version 1.1 or death, whichever occurs first) as primary outcome measure.\nMetabolic response is defined as fractional change (\u0394SUV and \u0394TLG), comparing the third en second scan with the baseline scan.", 
                "measure": "correlation between early metabolic response and PFS", 
                "safety_issue": "No", 
                "time_frame": "within 90 days after start of treatment"
            }, 
            {
                "description": "To quantify the correlation between early metabolic response and everolimus exposure (AUC0-24hr) on steady-state pharmacokinetics.\nMetabolic response is defined as fractional change (\u0394SUV and \u0394TLG), comparing the third en second scan with the baseline scan.", 
                "measure": "correlation between early metabolic response and AUC", 
                "safety_issue": "No", 
                "time_frame": "15 days after start of treatment"
            }, 
            {
                "description": "To explore, quantify and describe whether dose escalation in patients who are hypothetically underexposed will result in an increase in metabolic response.\nMetabolic response is defined as fractional change (\u0394SUV and \u0394TLG), comparing the third en second scan with the baseline scan.", 
                "measure": "effect dose escalation on metabolic respons", 
                "safety_issue": "No", 
                "time_frame": "within 36 days after start of treatment"
            }
        ], 
        "source": "Radboud University", 
        "sponsors": {
            "collaborator": {
                "agency": "Novartis", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Radboud University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}